Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1246-2965 | Other Identifier | World Health Organization |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to assess safety, tolerability, pharmacokinetics (PK), formulation (liquid and solid oral forms) and food effect of ABI-H3733 in healthy participants. Part 1 includes evaluation of the safety, tolerability, and PK of ABI-H3733 during single ascending dose (SAD) and multiple-ascending dose (MAD) administration of the oral liquid formulation. Part 2 includes assessment of a solid dosage formulation of ABI-H3733 in participants under fasted conditions or after a high-fat meal. Optional cohorts may be enrolled in Parts 1 and 2 of the study to explore additional dose levels, solid oral dosage formulations, or for cohort expansion.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part 1: SAD Cohorts 1-7 ABI-H3733 Liquid Form | Experimental | A single dose of ABI-H3733 liquid oral dosage form administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts. |
|
| Part 1: SAD Cohorts 1-7 Placebo Liquid Form | Placebo Comparator | A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered on Day 1. Cohort 1 will receive a 100-mg dose. Subsequent cohorts 2-7 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts. |
|
| Part 1: MAD Cohorts 8-10 ABI-H3733 Liquid Form | Experimental | Once-daily doses of ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts. |
|
| Part 1: MAD Cohorts 8-10 Placebo Liquid Form | Placebo Comparator | Once-daily doses of placebo matching ABI-H3733 liquid oral dosage form will be administered from Day 1 to Day 5. Cohort 8 will receive a dose determined from evaluation of the data from the SAD cohorts. Subsequent cohorts 9 and 10 will receive a ≤3-fold increase in dose from the previous cohort; the dose will be determined by evaluation of safety and PK data from previous cohorts. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABI-H3733 Liquid Oral Dosage Form | Drug | ABI-H3733 liquid oral dosage form |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants with One or More Adverse Events | Up to Day 10 | |
| Number of Participants with One or More Related Adverse Events | Up to Day 10 | |
| Number of Participants with One or More Severe (Grade ≥3) Adverse Events | Up to Day 10 |
| Measure | Description | Time Frame |
|---|---|---|
| SAD Cohorts 1-7: Area Under the Plasma Concentration Time Curve (AUC) of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing | |
| SAD Cohorts 1-7: Maximum Plasma Concentration (Cmax) ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Katia Alves, MD | Assembly Biosciences | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Auckland Clinical Studies | Auckland | New Zealand |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Part 2: Single Dose Fasted Cohort 11 ABI-H3733 Solid Form | Experimental | A single dose of ABI-H3733 solid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1. |
|
| Part 2: Single Dose Fasted Cohort 11 Placebo Solid Form | Placebo Comparator | A single dose of placebo matching ABI-H3733 liquid oral dosage form will be administered in a fasted state on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1. |
|
| Part 2: Single Dose Fed Cohort 12 ABI-H3733 Solid Form | Experimental | A single dose of ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1. |
|
| Part 2: Single Dose Fed Cohort 12 Placebo Solid Form | Placebo Comparator | A single dose of placebo matching ABI-H3733 solid oral dosage form will be administered after a high-fat meal on Day 1. The decision to proceed with Part 2 and the dose administered will be determined after evaluation of cumulative safety and PK data from Part 1. |
|
| ABI-H3733 Solid Oral Dosage Form | Drug | ABI-H3733 solid oral dosage form |
|
| Placebo to ABI-H3733 Liquid Oral Dosage Form | Drug | Placebo to ABI-H3733 liquid oral dosage form |
|
| Placebo to ABI-H3733 Solid Oral Dosage Form | Drug | Placebo to ABI-H3733 solid oral dosage form |
|
| SAD Cohorts 1-7: Time of Cmax (Tmax) of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| SAD Cohorts 1-7: Apparent Terminal Elimination Half-life (t1/2) of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| SAD Cohorts 1-7: Apparent Systemic Clearance (CL/F) of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| SAD Cohorts 1-7: Apparent Volume of Distribution (Vz/F) of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| MAD Cohorts 8-10: AUC of ABI-H3733 | before and at pre-specified time points up to 24 hours after dosing on Day 1; before and up to 120 hours after dosing on Day 5 |
| MAD Cohorts 8-10: Cmax Over the Dosing Interval of ABI-H3733 | before and at pre-specified time points up to 24 hours after dosing on Day 1; before and up to 120 hours after dosing on Day 5 |
| MAD Cohorts 8-10: Tmax of ABI-H3733 | before and at pre-specified time points up to 24 hours after dosing on Day 1; before and up to 120 hours after dosing on Day 5 |
| MAD Cohorts 8-10: t1/2 of ABI-H3733 | before and at pre-specified time points up to 24 hours after dosing on Day 1; before and up to 120 hours after dosing on Day 5 |
| Single Dose Cohorts 11-12: AUC of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| Single Dose Cohorts 11-12: Cmax of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| Single Dose Cohorts 11-12: Tmax of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| Single Dose Cohorts 11-12: t1/2 of ABI-H3733 | before and at pre-specified time points up to 120 hours after dosing |
| ID | Term |
|---|---|
| D019694 | Hepatitis B, Chronic |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided